Brian Druker

Director

  • 61309 Citations
  • 105 h-Index
1981 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 25 Similar Profiles
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Tyrosine Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Phosphorylation Medicine & Life Sciences
Mutation Medicine & Life Sciences
Piperazines Medicine & Life Sciences
bcr-abl Fusion Proteins Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1987 2017

MUTAGENESIS OF POLYOMA MIDDLE-T ANTIGEN

Druker, B.

National Institutes of Health

4/13/87 → …

Project: Research projectPostdoctoral Individual National Research Service Award

Accelerating target identification and validation in leukemia: Integrating siRNA-

Druker, B.

National Institutes of Health

9/30/098/31/11

Project: Research projectNIH Challenge Grants and Partnerships Program

Small Interfering RNA
Leukemia
Neoplasms
RNA Interference
Gene Expression

Cancer and Kinases

Druker, B.

National Institutes of Health

9/1/058/31/06

Project: Research projectConference

Phosphotransferases
Pharmaceutical Preparations
Neoplasms
Clinical Trials
Enzymes

TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS

Druker, B.

National Institutes of Health

7/9/996/30/04

Project: Research projectMidcareer Investigator Award in Patient-Oriented Research

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antineoplastic Agents
Protein-Tyrosine Kinases
Clinical Trials, Phase I
Hematopoietic Stem Cells

CBL FUNCTION IN CELLULAR SIGNALING AND TRANSFORMATION

Druker, B.

National Institutes of Health

1/1/9912/31/04

Project: Research projectResearch Project

Tyrosine
Phosphorylation
src Homology Domains
Protein-Tyrosine Kinases
Research Personnel

Research Output 1981 2018

A novel AGGF1-PDGFRβ fusion in pediatric T-cell acute lymphoblastic leukemia

Zabriskie, M. S., Antelope, O., Verma, A. R., Draper, L. R., Eide, C. A., Pomicter, A. D., Tran, T. H., Druker, B. J., Tyner, J. W., Miles, R. R., Graham, J. M., Hwang, J. Y., Varley, K. E., Toydemir, R. M., Deininger, M. W., Raetz, E. A. & O’Hare, T. Jan 31 2018 In : Haematologica. 103, 2, p. e87-e91

Research output: Contribution to journalComment/debate

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics

Chronic myelogenous leukemia: Pregnancy in the era of stopping tyrosine kinase inhibitor therapy

Berman, E., Druker, B. J. & Burwick, R. Apr 20 2018 In : Journal of Clinical Oncology. 36, 12, p. 1250-1256 7 p.

Research output: Contribution to journalReview article

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Pregnancy
Therapeutics

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

Hosseini, M. M., Kurtz, S. E., Abdelhamed, S., Mahmood, S., Davare, M. A., Kaempf, A., Elferich, J., McDermott, J. E., Liu, T., Payne, S. H., Shinde, U., Rodland, K. D., Mori, M., Druker, B. J., Singer, J. W. & Agarwal, A. Mar 29 2018 (Accepted/In press) In : Leukemia. p. 1-14 14 p.

Research output: Contribution to journalArticle

Interleukin-1 Receptor-Associated Kinases
Acute Myeloid Leukemia
Myeloid Cells
Therapeutics
Heterografts

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms

MacHado-Neto, J. A., Fenerich, B. A., Scopim-Ribeiro, R., Eide, C. A., Coelho-Silva, J. L., Dechandt, C. R. P., Fernandes, J. C., Rodrigues Alves, A. P. N., Scheucher, P. S., Simões, B. P., Alberici, L. C., De Figueiredo Pontes, L. L., Tognon, C. E., Druker, B. J., Rego, E. M. & Traina, F. Mar 1 2018 In : Cell Death and Disease. 9, 3, 311

Research output: Contribution to journalArticle

Metformin
Neoplasms
Polycythemia Vera
Cell Survival
Cell Proliferation

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples

Edwards V, D. K., Sweeney, D. T., Ho, H., Eide, C. A., Rofelty, A., Agarwal, A., Liu, S. Q., Danilov, A. V., Lee, P., Chantry, D., McWeeney, S. K., Druker, B. J., Tyner, J. W., Spurgeon, S. E. & Loriaux, M. M. May 15 2018 In : Oncotarget. 9, 37, p. 24576-24589 14 p.

Research output: Contribution to journalArticle

Colony-Stimulating Factor Receptors
Macrophage Colony-Stimulating Factor
B-Cell Chronic Lymphocytic Leukemia
Antineoplastic Agents
Monocytes